- Second tranche of €10M from €25M growth capital loan signed with the European Investment Bank in May 2019
- New funds will be used to accelerate the development, manufacturing and commercialisation of in vitro diagnostics for infectious diseases
Mobidiag Ltd. today announces that it has received the second tranche of €10M from the €25M growth capital loan signed with the European Investment Bank Group (EIB) in May 2019. These new funds will be used to advance Mobidiag’s research and development and facilitate further validation and commercialisation of new molecular diagnostics tests using the Company’s Amplidiag® and Novodiag® platforms.
The loan is supported by the Continue Reading
- CE-IVD marked molecular diagnostic tests on the Novodiag and Amplidiag platforms for rapid detection of COVID-19 infections to support decisions for efficient patient isolation, treatment and release
- Antibody test for detection of past COVID-19 infections
- Secure supply chain and in-house manufacturing capabilities to meet demand
Mobidiag Ltd. today announces that it has received CE-IVD markings for its Novodiag® COVID-19 and Amplidiag® COVID-19 molecular diagnostic tests for the early detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19).
These tests complement the Company’s already available antibody test, Continue Reading
- Real-time RT-PCR-based test enables fast, on demand and fully automated detection of early COVID-19 infections for rapid isolation and treatment guidance;
- provides safety for users with a closed system;
- easy to use with no need for highly trained personnel enabling decentralized testing.
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received emergency use authorization in Finland for its Novodiag® COVID-19 molecular diagnostic test for the rapid and fully automated detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Continue Reading
– Real-time PCR-based test enables high-throughput reliable detection of early COVID-19 infections for rapid isolation and treatment guidance
– Currently set up for routine use in main Finnish clinical labs with capacity to test up to 4,000 samples per day
Mobidiag Ltd. announces that it has received emergency use authorization in Finland for its Amplidiag® COVID-19 molecular diagnostic test for the rapid detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Amplidiag® COVID-19 is now available for use in Finland*. The test will be run for routine use at the main clinical laboratories in Finland (Helsinki University Hospital (Huslab), SYNLAB and Mehiläinen) doubling Finnish testing capacity and allowing testing coverage for most of the country. The process for obtaining emergency use authorizat
Mobidiag is now offering a rapid and easy to use immunoassay to detect coronavirus (COVID-19) infection.
The Anti-SARS-CoV-2 Rapid Test uses the lateral flow technology and allows detection of IgG and IgM from human serum, whole blood or plasma in about 15 minutes.
Developed by Autobio Diagnostics, key partner of Mobidiag and leading clinical diagnostics company in the Chinese the market, the Anti-SARS-CoV-2 test is now available through Mobidiag sales channels as well as our local distributors (except in Portugal, the Netherlands and Ukraine).
Novodiag® assay rapidly detects coronavirus and influenzas;
provides safety for users with a closed system;
easy to use with no need for highly trained personnel in high risk and hard to reach areas
Mobidiag Ltd. today announces that it has initiated development of a Novodiag® molecular diagnostic test for the rapid and simultaneous detection of the novel coronavirus (strain 2019-nCoV) and influenza viruses.
The assay is being developed in partnership with Autobio Diagnostics (Autobio), the market leading Chinese clinical diagnostics company, and Automobi Molecular Diagnostics (Automobi), the joint venture launched by Mobidiag and Autobio in May 2019.
ESPOO, Finland, January 07, 2020 – Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has been granted EUR 1.5 million ($1.65 million) additional funding from Business Finland (formerly Tekes) for the continued development of a rapid diagnostic test for sepsis using Mobidiag’s Novodiag platform. This additional funding has been secured as a result of strong progress in the development of the assay and the completion of key milestones by Mobidiag since the award of the first grant in May 2018. The new funding brings the total loan to EUR 3 million ($3.3 million).
PARIS, France, December 11th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, will host a symposium at the 39th Interdisciplinary Meeting of Anti-Infectious Chemotherapy (RICAI) conference in Paris, from the 16th to 17th of December.
The RICAI conference is an annual meeting bringing together leading French clinicians and microbiologists (parasitologists, virologists, bacteriologists) and innovative commercial companies in diagnostics.
ESPOO, Finland, December 10, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces the appointment of Joseph E. Bernardo as Senior Strategic Advisor to the Company.
Mr. Bernardo has over twenty years of experience in the diagnostics industry including a significant tenure as a President at Thermo Fisher Scientific, working across a number of divisions including Clinical Next-Generation Sequencing and Oncology, Immuno-Diagnostics, Anatomic Pathology and Fisher HealthCare, the hospital laboratory distribution business of Thermo Fisher.
Agreements signed in Poland, Ukraine, Romania and Israel, with more in discussions.
ESPOO, Finland, October 29th, 2019 – Mobidiag Ltd., a molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has signed new exclusive agreements with international partners for the distribution of its Amplidiag® and Novodiag® products in Europe and the Middle East.
Mobidiag has signed exclusive agreements for the distribution of Amplidiag® and Novodiag® with ALAB Ltd. for Poland and Ukraine, BIOgenetiX for Romania and Theranostica Ltd. for Israel.